Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal...
Toggle Summary Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Current Business Plan Expected to Extend Cash Position and Fund Operations into Q2 2018...
Toggle Summary Agile Therapeutics to Present at 29th Annual ROTH Conference
Presentation Scheduled on Monday, March 13, 2017 at 4:30 PM Pacific Time...
Toggle Summary Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
Presentation Scheduled on February 23, 2017 at 10:00 AM ET...
Toggle Summary Agile Therapeutics to Present at the 2017 BIO CEO & Investor Conference
Presentation Scheduled on Monday, February 13th, 2017 at 11:00 am ET...
Toggle Summary Agile Therapeutics to Present at Noble Capital Markets' Thirteenth Annual Investor/Equity Conference
Presentation Scheduled on Tuesday, January 31, 2017 at 11:00 am ET...
Toggle Summary Agile Therapeutics Announces Positive Top-line Phase 3 Results
Resubmission of Twirla ® New Drug Application Expected to Address FDA's Complete Response Letter Company Plans to Resubmit NDA in First Half of 2017              Company to Host Conference Call on January 3, 2017 at 5:00 p.m. Eastern Time                PRINCETON, N.J., Jan....
Toggle Summary Agile Therapeutics to Present at Biotech Showcase 2017
Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time...
Toggle Summary Agile Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation Scheduled on Thursday, January 12th, 2017 at 11:30 AM Pacific Time ...
Toggle Summary Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey's Technology Business Tax Certificate Transfer Program
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company announced today that it has received net proceeds of approximately $3 million in non-dilutive financing through the State of New Jersey's Technology Business...
Shadow